Christopher Ruel

1.6k total citations
47 papers, 1.0k citations indexed

About

Christopher Ruel is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christopher Ruel has authored 47 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 18 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christopher Ruel's work include Cancer Treatment and Pharmacology (12 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Multiple Myeloma Research and Treatments (6 papers). Christopher Ruel is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Multiple Myeloma Research and Treatments (6 papers). Christopher Ruel collaborates with scholars based in United States. Christopher Ruel's co-authors include Paul Frankel, David R. Gandara, Przemyslaw Twardowski, Primo N. Lara, Marianna Koczywas, Suresh S. Ramalingam, Barbara J. Gitlitz, Igor Espinoza‐Delgado, Chandra P. Belani and David R. Gandara and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Christopher Ruel

43 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Ruel United States	18	536	468	309	154	131	47	1.0k
Qingfang Li China	17	336 0.6×	437 0.9×	222 0.7×	175 1.1×	235 1.8×	37	1.0k
Laurence Cooke United States	19	505 0.9×	532 1.1×	207 0.7×	215 1.4×	105 0.8×	39	1.1k
Roger Mouawad France	21	308 0.6×	523 1.1×	155 0.5×	208 1.4×	177 1.4×	57	968
Sujatha Jagadeeswaran United States	12	360 0.7×	465 1.0×	169 0.5×	100 0.6×	197 1.5×	16	973
A. W. Tolcher United States	19	583 1.1×	821 1.8×	310 1.0×	168 1.1×	201 1.5×	107	1.3k
Philipp Manegold United States	14	446 0.8×	404 0.9×	124 0.4×	156 1.0×	147 1.1×	23	919
William Dahut United States	11	323 0.6×	464 1.0×	287 0.9×	71 0.5×	190 1.5×	19	887
Shanshan Liu China	17	276 0.5×	599 1.3×	265 0.9×	144 0.9×	211 1.6×	36	1.1k
K. Papadopoulos United States	16	540 1.0×	598 1.3×	215 0.7×	299 1.9×	131 1.0×	56	1.1k
Vijay Peddareddigari United States	11	600 1.1×	714 1.5×	183 0.6×	111 0.7×	170 1.3×	18	1.2k

Countries citing papers authored by Christopher Ruel

Since Specialization

Citations

This map shows the geographic impact of Christopher Ruel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Ruel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Ruel more than expected).

Fields of papers citing papers by Christopher Ruel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Ruel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Ruel. The network helps show where Christopher Ruel may publish in the future.

Co-authorship network of co-authors of Christopher Ruel

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Ruel. A scholar is included among the top collaborators of Christopher Ruel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Ruel. Christopher Ruel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Egelston, Colt A., Susan E. Yost, Paul Frankel, et al.. (2024). A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.. Journal of Clinical Oncology. 42(16_suppl). 1038–1038. 1 indexed citations

Frankel, Paul, Pamela B. Allen, Leslie Popplewell, et al.. (2024). Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica. 110(1). 142–152. 3 indexed citations

Lange, Leslie A., Peter Lee, Marcin Kortylewski, et al.. (2024). Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP). International Journal of Radiation Oncology*Biology*Physics. 120(2). S147–S148. 1 indexed citations

Egelston, Colt A., Weihua Guo, Susan E. Yost, et al.. (2023). Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer. Cancer Immunology Immunotherapy. 72(9). 3013–3027. 14 indexed citations

Yuan, Yuan, Susan E. Yost, Yujie Cui, et al.. (2023). Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer. The Oncologist. 28(7). e498–e507. 9 indexed citations

Lavasani, Sayeh, George Somlo, Susan E. Yost, et al.. (2022). Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer. Cancer. 129(5). 740–749. 5 indexed citations

Yuan, Yuan, Jin Sun Lee, Susan E. Yost, et al.. (2021). Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. European Journal of Cancer. 154. 11–20. 61 indexed citations

Koczywas, Marianna, Paul Frankel, Jonathan W. Riess, et al.. (2020). Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin.. Journal of Clinical Oncology. 38(15_suppl). 9055–9055. 1 indexed citations

Poh, Christina, Paul Frankel, Christopher Ruel, et al.. (2019). Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 134(Supplement_1). 760–760. 25 indexed citations

10.

Hardwick, Nicola, Paul Frankel, Christopher Ruel, et al.. (2018). p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clinical Cancer Research. 24(6). 1315–1325. 54 indexed citations

11.

Morgan, Robert J., Timothy W. Synold, Jeff Longmate, et al.. (2015). Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemotherapy and Pharmacology. 76(5). 897–907. 26 indexed citations

12.

Frankel, Paul, Timothy W. Synold, Joanne Mortimer, et al.. (2014). Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. British Journal of Cancer. 111(12). 2268–2274. 14 indexed citations

13.

Kirschbaum, Mark, Kenneth A. Foon, Paul Frankel, et al.. (2013). A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leukemia & lymphoma. 55(10). 2301–2304. 59 indexed citations

14.

Tarhini, Ahmad A., Paul Frankel, Kim Margolin, et al.. (2011). Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. Clinical Cancer Research. 17(20). 6574–6581. 62 indexed citations

15.

Somlo, George, Cynthia L. Martel, Sean K. Lau, et al.. (2011). A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Research and Treatment. 131(3). 899–906. 22 indexed citations

16.

Sahebi, Firoozeh, Paul Frankel, Len Farol, et al.. (2011). Sequential Bortezomib, Dexamethasone, and Thalidomide Maintenance Therapy after Single Autologous Peripheral Stem Cell Transplantation in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation. 18(3). 486–492. 12 indexed citations

17.

Ramalingam, Suresh S., Chandra P. Belani, Christopher Ruel, et al.. (2009). Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 4(1). 97–101. 133 indexed citations

18.

Chu, Peiguo, Sean K. Lau, Lawrence M. Weiss, et al.. (2008). Assessment of low prostate weight as a determinant of a higher positive margin rate after laparoscopic radical prostatectomy: a prospective pathologic study of 1,500 cases. Surgical Endoscopy. 23(5). 1058–1064. 8 indexed citations

19.

Sahebi, Firoozeh, Ricardo Spielberger, Neil Kogut, et al.. (2006). Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplantation. 37(9). 825–829. 26 indexed citations

20.

Lara, Primo N., Karen Giselle Chee, Jeff Longmate, et al.. (2004). Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma. Cancer. 100(10). 2125–2131. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact